Yanyun Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanyun Xie has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Lijian Tao
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; National Medical Metabolomics International Collaborative Research Center, Xiangya Hospital, Central South University, Changsha, China
6 shared publicationsXin Lv
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; Department of Nuclear Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
5 shared publicationsYan Zhang
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; National Medical Metabolomics International Collaborative Research Center, Xiangya Hospital, Central South University, Changsha, China
5 shared publicationsJie Meng
Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; Department of Pulmonary and Critical Care Medicine, Third Xiangya Hospital, Central South University, Changsha, China
4 shared publicationsGaoyun Hu
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China
3 shared publicationsJiajia Li
Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China
3 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (42) , e75449
Caveolin‐1 Stabilizes SERCA2 to Counteract Acute Kidney Injury via Suppression of Ca 2+ ‐Dependent Endoplasmic Reticulum Stress in Distal Tubules
Acute kidney injury (AKI) is a severe clinical condition with high morbidity and mortality. Caveolin‐1 (Cav‐1), a main structural protein of caveolae, orchestrates key cellular processes including endocytosis, lipid transport, and signal transduction by serving as a platform. However, its specific role in AKI remains unclear. Here, we report that Cav‐1 is upregulated in distal tubule epithelial cells (TECs) in both AKI patients and mouse models induced by ischemia/reperfusion injury (IRI) and lipopolysaccharide (LPS). Global and distal TEC‐specific Cav1 knockout exacerbates IRI and LPS‐induced AKI. RNA‐seq reveals that Cav‐1 deficiency exacerbates intracellular calcium ion (Ca 2+ ) homeostasis imbalance and endoplasmic reticulum (ER) stress in injured kidney tissues. Mechanistically, Cav‐1 interacts with sarcoplasmic/endoplasmic reticulum Ca 2+ ‐ATPase 2 (SERCA2), a key regulator of intracellular Ca 2+ homeostasis, through its scaffolding domain, promoting SERCA2 deubiquitination and stability in the ER, thereby maintaining intracellular Ca 2+ homeostasis and suppressing ER stress in distal TECs. Furthermore, supplementation with a cell‐permeable Cav‐1 scaffolding domain peptide (CSP) or activation of SERCA2 with a small‐molecule agonist CDN1163 alleviates IRI‐ and LPS‐induced AKI, while distal TEC‐specific SERCA2 knockdown abrogates CSP's therapeutic effect. Together, these findings reveal a novel Cav‐1‐mediated pathway and highlight its potential as a therapeutic target for AKI.
- 8 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (42) , e75449
Open AccessCaveolin‐1 Stabilizes SERCA2 to Counteract Acute Kidney Injury via Suppression of Ca 2+ ‐Dependent Endoplasmic Reticulum Stress in Distal Tubules
Acute kidney injury (AKI) is a severe clinical condition with high morbidity and mortality. Caveolin‐1 (Cav‐1), a main structural protein of caveolae, orchestrates key cellular processes including endocytosis, lipid transport, and signal transduction by serving as a platform. However, its specific role in AKI remains unclear. Here, we report that Cav‐1 is upregulated in distal tubule epithelial cells (TECs) in both AKI patients and mouse models induced by ischemia/reperfusion injury (IRI) and lipopolysaccharide (LPS). Global and distal TEC‐specific Cav1 knockout exacerbates IRI and LPS‐induced AKI. RNA‐seq reveals that Cav‐1 deficiency exacerbates intracellular calcium ion (Ca 2+ ) homeostasis imbalance and endoplasmic reticulum (ER) stress in injured kidney tissues. Mechanistically, Cav‐1 interacts with sarcoplasmic/endoplasmic reticulum Ca 2+ ‐ATPase 2 (SERCA2), a key regulator of intracellular Ca 2+ homeostasis, through its scaffolding domain, promoting SERCA2 deubiquitination and stability in the ER, thereby maintaining intracellular Ca 2+ homeostasis and suppressing ER stress in distal TECs. Furthermore, supplementation with a cell‐permeable Cav‐1 scaffolding domain peptide (CSP) or activation of SERCA2 with a small‐molecule agonist CDN1163 alleviates IRI‐ and LPS‐induced AKI, while distal TEC‐specific SERCA2 knockdown abrogates CSP's therapeutic effect. Together, these findings reveal a novel Cav‐1‐mediated pathway and highlight its potential as a therapeutic target for AKI.
- Open Access
- 30 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1540
Urinary Tract Infections Detection with Molecular Biomarkers
Urinary tract infection (UTI) is the most prevalent kind of pathogenic bacteria infection, and the midstream urine culture is regarded as the gold standard in UTI diagnosis. Recently, even with modern media and techniques such as polymerase chain reaction (PCR), urinary cultures still create a considerable workload for hospital laboratories. Other UTI-detecting methods, such as flow cytometry and lateral flow immunoassay, suffer from various drawbacks like long time consumption and low sensitivity. Therefore, looking for reliable biomarkers in UTI is urgently needed. In this review, the current definitions of UTI can be basically divided into two main categories: uncomplicated UTI and complicated UTI. In light of anatomical sites, it can be classified as either lower UTI or upper UTI. We take the classification of UTI as a clue and review the reported extensive literature to classify the existing studied markers into the following three categories: Biomarkers used clinically; Promising biomarkers; and Controversial biomarkers. Particularly, the nucleic acid-associated, metabolomic, and lipidomic biomarkers are highlighted. At the end, we discuss the challenges and prospects of biomarkers in UTI, hoping to further inspire the diagnosis of UTI.
- 30 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1540
Open AccessUrinary Tract Infections Detection with Molecular Biomarkers
Urinary tract infection (UTI) is the most prevalent kind of pathogenic bacteria infection, and the midstream urine culture is regarded as the gold standard in UTI diagnosis. Recently, even with modern media and techniques such as polymerase chain reaction (PCR), urinary cultures still create a considerable workload for hospital laboratories. Other UTI-detecting methods, such as flow cytometry and lateral flow immunoassay, suffer from various drawbacks like long time consumption and low sensitivity. Therefore, looking for reliable biomarkers in UTI is urgently needed. In this review, the current definitions of UTI can be basically divided into two main categories: uncomplicated UTI and complicated UTI. In light of anatomical sites, it can be classified as either lower UTI or upper UTI. We take the classification of UTI as a clue and review the reported extensive literature to classify the existing studied markers into the following three categories: Biomarkers used clinically; Promising biomarkers; and Controversial biomarkers. Particularly, the nucleic acid-associated, metabolomic, and lipidomic biomarkers are highlighted. At the end, we discuss the challenges and prospects of biomarkers in UTI, hoping to further inspire the diagnosis of UTI.
- Open Access
- 5 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1188615
Corrigendum: Protective effects of Mefunidone on ischemia-reperfusion injury/folic acid-induced acute kidney injury
Corrigendum: Protective effects of Mefunidone on ischemia-reperfusion injury/folic acid-induced acute kidney injury
- 5 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1188615
Open AccessCorrigendum: Protective effects of Mefunidone on ischemia-reperfusion injury/folic acid-induced acute kidney injury
Corrigendum: Protective effects of Mefunidone on ischemia-reperfusion injury/folic acid-induced acute kidney injury
- Open Access
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1043945
Protective effects of mefunidone on ischemia-reperfusion injury/Folic acid-induced acute kidney injury
Renal ischemia-reperfusion injury (IRI) is one of the most common causes of acute kidney injury (AKI). It poses a significant threat to public health, and effective therapeutic drugs are lacking. Mefunidone (MFD) is a new pyridinone drug that exerts a significant protective effect on diabetic nephropathy and the unilateral ureteral obstruction (UUO) model in our previous study. However, the effects of mefunidone on ischemia-reperfusion injury-induced acute kidney injury remain unknown. In this study, we investigated the protective effect of mefunidone against ischemia-reperfusion injury-induced acute kidney injury and explored the underlying mechanism. These results revealed that mefunidone exerted a protective effect against ischemia-reperfusion injury-induced acute kidney injury. In an ischemia-reperfusion injury-induced acute kidney injury model, treatment with mefunidone significantly protected the kidney by relieving kidney tubular injury, suppressing oxidative stress, and inhibiting kidney tubular epithelial cell apoptosis. Furthermore, we found that mefunidone reduced mitochondrial damage, regulated mitochondrial-related Bax/bcl2/cleaved-caspase3 apoptotic protein expression, and protected mitochondrial electron transport chain complexes III and V levels both in vivo and in vitro, along with a protective effect on mitochondrial membrane potential in vitro. Given that folic acid (FA)-induced acute kidney injury is a classic model, we used this model to further validate the efficacy of mefunidone in acute kidney injury and obtained the same conclusion. Based on the above results, we conclude that mefunidone has potential protective and therapeutic effects in both ischemia-reperfusion injury- and folic acid-induced acute kidney injury.
- 23 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1043945
Open AccessProtective effects of mefunidone on ischemia-reperfusion injury/Folic acid-induced acute kidney injury
Renal ischemia-reperfusion injury (IRI) is one of the most common causes of acute kidney injury (AKI). It poses a significant threat to public health, and effective therapeutic drugs are lacking. Mefunidone (MFD) is a new pyridinone drug that exerts a significant protective effect on diabetic nephropathy and the unilateral ureteral obstruction (UUO) model in our previous study. However, the effects of mefunidone on ischemia-reperfusion injury-induced acute kidney injury remain unknown. In this study, we investigated the protective effect of mefunidone against ischemia-reperfusion injury-induced acute kidney injury and explored the underlying mechanism. These results revealed that mefunidone exerted a protective effect against ischemia-reperfusion injury-induced acute kidney injury. In an ischemia-reperfusion injury-induced acute kidney injury model, treatment with mefunidone significantly protected the kidney by relieving kidney tubular injury, suppressing oxidative stress, and inhibiting kidney tubular epithelial cell apoptosis. Furthermore, we found that mefunidone reduced mitochondrial damage, regulated mitochondrial-related Bax/bcl2/cleaved-caspase3 apoptotic protein expression, and protected mitochondrial electron transport chain complexes III and V levels both in vivo and in vitro, along with a protective effect on mitochondrial membrane potential in vitro. Given that folic acid (FA)-induced acute kidney injury is a classic model, we used this model to further validate the efficacy of mefunidone in acute kidney injury and obtained the same conclusion. Based on the above results, we conclude that mefunidone has potential protective and therapeutic effects in both ischemia-reperfusion injury- and folic acid-induced acute kidney injury.
- Open Access
- 4 November 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-12
Role of SERCA3 in the Prognosis and Immune Function in Pan-Cancer
The sarcoendoplasmic reticulum calcium adenosine triphosphatase (ATPase) 3 (SERCA3), a member of the SERCA protein family, is located at the endoplasmic reticulum. Its main function is to pump Ca2+ into the endoplasmic reticulum and is involved in maintaining intracellular calcium homeostasis and signal transduction, which are very important factors impacting cancer development and progression. However, the specific role of SERCA3 in cancer remains unclear. Our study, for the first time, comprehensively analyzed the SERCA3 expression profile in multiple cancers and its prognostic value in different cancers using bioinformatics. Furthermore, TCGA database was applied to evaluate the certain correlation of SERCA3 expression with immune modulator genes, immune checkpoints, immune cell infiltration, TMB, and MSI. The results revealed that in many cancers, SERCA3 expression was markedly decreased, which was related to poor prognosis. Additionally, we noticed that SERCA3 expression was correlated with TNM classification and WHO cancer stages in some cancer types. The Pearson correlation analysis showed that SERCA3 expression was closely associated with chemokines, chemokine receptors, MHC, immune activation genes, and immunosuppressive genes. In most cancer types, SERCA3 expression was also associated with immune checkpoints, including PDCD1 and CTLA-4. Further analysis suggested that SERCA3 was significantly correlated with CD8+ T cells, and regulatory T cells. Additionally, pan-cancer analysis confirmed that SERCA3 expression was related to TMB and MSI. In conclusion, these results offer a new insight into the functions and effects of SERCA3 in pan-cancer, and further provide some basis for considering SERCA3 as a potential cancer treatment target and biomarker.
- 4 November 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-12
Open AccessRole of SERCA3 in the Prognosis and Immune Function in Pan-Cancer
The sarcoendoplasmic reticulum calcium adenosine triphosphatase (ATPase) 3 (SERCA3), a member of the SERCA protein family, is located at the endoplasmic reticulum. Its main function is to pump Ca2+ into the endoplasmic reticulum and is involved in maintaining intracellular calcium homeostasis and signal transduction, which are very important factors impacting cancer development and progression. However, the specific role of SERCA3 in cancer remains unclear. Our study, for the first time, comprehensively analyzed the SERCA3 expression profile in multiple cancers and its prognostic value in different cancers using bioinformatics. Furthermore, TCGA database was applied to evaluate the certain correlation of SERCA3 expression with immune modulator genes, immune checkpoints, immune cell infiltration, TMB, and MSI. The results revealed that in many cancers, SERCA3 expression was markedly decreased, which was related to poor prognosis. Additionally, we noticed that SERCA3 expression was correlated with TNM classification and WHO cancer stages in some cancer types. The Pearson correlation analysis showed that SERCA3 expression was closely associated with chemokines, chemokine receptors, MHC, immune activation genes, and immunosuppressive genes. In most cancer types, SERCA3 expression was also associated with immune checkpoints, including PDCD1 and CTLA-4. Further analysis suggested that SERCA3 was significantly correlated with CD8+ T cells, and regulatory T cells. Additionally, pan-cancer analysis confirmed that SERCA3 expression was related to TMB and MSI. In conclusion, these results offer a new insight into the functions and effects of SERCA3 in pan-cancer, and further provide some basis for considering SERCA3 as a potential cancer treatment target and biomarker.
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 2453617
Fluorofenidone Inhibits UUO/IRI‐Induced Renal Fibrosis by Reducing Mitochondrial Damage
Objective. Mitochondrial damage contributes to extracellular matrix (ECM) deposition and renal fibrosis. In this study, we aimed (1) to investigate whether fluorofenidone (AKF‐PD) can attenuate mitochondrial damage in two renal fibrosis models: unilateral ureteral obstruction (UUO) and renal ischemia‐reperfusion injury (IRI), and (2) to explore the underlying mechanism. Method. Mitochondrial damage and renal lesions were analyzed in the UUO and IRI models. Mitochondrial energy metabolism, mitochondrial biogenesis, and oxidative stress were measured to assess the effect of AKF‐PD on mitochondrial damage and to explore the underlying mechanism. In addition, HK‐2 cells were stimulated with TGF‐β with and without AKF‐PD. The mitochondrial morphology, mtROS, ATP contents, and redox‐related proteins were then examined. Results. In both UUO and IRI models, AKF‐PD relieved renal fibrosis, maintained mitochondrial structure, and increased mitochondrial DNA copy numbers. The protection was associated with (1) sustaining mitochondrial energy metabolism, evident by elevations of tricarboxylic acid (TCA) cycle enzymes and mitochondrial respiratory chain complexes; (2) improving mitochondrial biogenesis with increases of TFAM, NRF1, PGC‐1α, and SIRT1; and (3) reducing mitochondrial oxidative stress likely via regulating SOD2, SIRT3, and NOX4 expressions. In HK‐2 cells treated with TGF‐β, AKF‐PD protected mitochondria along with improving mitochondrial morphology, enhancing ATP production, reducing mtROS, and regulating SOD2, SIRT3, and NOX4 expression. Conclusion. We demonstrate that AKF‐PD inhibited renal fibrosis at least in part via protecting mitochondria from damages developed in the UUO and IRI models. The mitochondrial protection was associated with sustaining mitochondrial energy metabolism, improving mitochondrial biogenesis, and reducing mitochondrial oxidative stress. This research verified the protective effect of AKF‐PD on mitochondria in the UUO and IRI models and elaborated the underlying mechanism.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 2453617
Open AccessFluorofenidone Inhibits UUO/IRI‐Induced Renal Fibrosis by Reducing Mitochondrial Damage
Objective. Mitochondrial damage contributes to extracellular matrix (ECM) deposition and renal fibrosis. In this study, we aimed (1) to investigate whether fluorofenidone (AKF‐PD) can attenuate mitochondrial damage in two renal fibrosis models: unilateral ureteral obstruction (UUO) and renal ischemia‐reperfusion injury (IRI), and (2) to explore the underlying mechanism. Method. Mitochondrial damage and renal lesions were analyzed in the UUO and IRI models. Mitochondrial energy metabolism, mitochondrial biogenesis, and oxidative stress were measured to assess the effect of AKF‐PD on mitochondrial damage and to explore the underlying mechanism. In addition, HK‐2 cells were stimulated with TGF‐β with and without AKF‐PD. The mitochondrial morphology, mtROS, ATP contents, and redox‐related proteins were then examined. Results. In both UUO and IRI models, AKF‐PD relieved renal fibrosis, maintained mitochondrial structure, and increased mitochondrial DNA copy numbers. The protection was associated with (1) sustaining mitochondrial energy metabolism, evident by elevations of tricarboxylic acid (TCA) cycle enzymes and mitochondrial respiratory chain complexes; (2) improving mitochondrial biogenesis with increases of TFAM, NRF1, PGC‐1α, and SIRT1; and (3) reducing mitochondrial oxidative stress likely via regulating SOD2, SIRT3, and NOX4 expressions. In HK‐2 cells treated with TGF‐β, AKF‐PD protected mitochondria along with improving mitochondrial morphology, enhancing ATP production, reducing mtROS, and regulating SOD2, SIRT3, and NOX4 expression. Conclusion. We demonstrate that AKF‐PD inhibited renal fibrosis at least in part via protecting mitochondria from damages developed in the UUO and IRI models. The mitochondrial protection was associated with sustaining mitochondrial energy metabolism, improving mitochondrial biogenesis, and reducing mitochondrial oxidative stress. This research verified the protective effect of AKF‐PD on mitochondria in the UUO and IRI models and elaborated the underlying mechanism.
- 28 December 2021
- Vol. 46 (12) , 1403-1408
Research advance in the mechanism for oxidative stress-induced podocyte injury in diabetic kidney disease.
Diabetic kidney disease (DKD) is one of the serious microvascular complications of diabetes mellitus (DM), and it is also the leading cause for the end-stage kidney disease (ESKD), but the clinical treatment for it is limited at present. The pathogenesis of DKD is complex. Many studies have shown that podocyte injury is the core event of DKD, and oxidative stress is closely related to podocyte injury in DKD. Oxidative stress mediates podocyte apoptosis and slit diaphragm damage in DKD through various pathways. The antioxidant drugs can slow down the progression of DKD through reducing podocyte injury and are expected to enter clinical trials. The research status of antioxidant drugs is very important, which will provide new strategies for the clinical treatment of DKD.
- 28 December 2021
- Vol. 46 (12) , 1403-1408
Research advance in the mechanism for oxidative stress-induced podocyte injury in diabetic kidney disease.
Diabetic kidney disease (DKD) is one of the serious microvascular complications of diabetes mellitus (DM), and it is also the leading cause for the end-stage kidney disease (ESKD), but the clinical treatment for it is limited at present. The pathogenesis of DKD is complex. Many studies have shown that podocyte injury is the core event of DKD, and oxidative stress is closely related to podocyte injury in DKD. Oxidative stress mediates podocyte apoptosis and slit diaphragm damage in DKD through various pathways. The antioxidant drugs can slow down the progression of DKD through reducing podocyte injury and are expected to enter clinical trials. The research status of antioxidant drugs is very important, which will provide new strategies for the clinical treatment of DKD.
- 1 January 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 534, 694-701
Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy
- 1 January 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 534, 694-701
Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy